Media Center
Press Releases
2020
2019
Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.
9 December 2019/by Peggy BickertonTaiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates
7 June 2019/by Peggy BickertonBritish Company Behind Groundbreaking Breast Cancer Treatment
7 June 2019/by webadminAstex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
12 April 2019/by webadmin2018
Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
30 July 2018/by Renee HansenAstex’s Harren Jhoti Made Fellow of the Royal Society
9 May 2018/by webadminAstex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation
15 March 2018/by webadminHarren Jhoti Receives Lifetime Achievement Award from the UK BioIndustry Association
26 January 2018/by webadminOtsuka Signs Statement of Support for Women’s Empowerment Principles
19 January 2018/by Peggy Bickerton2017
2016
Astex to Showcase Its Next-Generation Hypomethylating Agents Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology
29 November 2016/by webadminAstex Joins the Dementia Discovery Fund as a Strategic Investor
21 November 2016/by webadminAstex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (ribociclib) plus letrozole as a first-line treatment for HR+/HER2- Advanced Breast Cancer
1 November 2016/by webadminPositive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka’s Subsidiary Astex Pharmaceuticals
20 October 2016/by webadminAstex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
19 April 2016/by webadmin2015
2014
2019
- Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL. 9 December 2019
- Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates 7 June 2019
- British Company Behind Groundbreaking Breast Cancer Treatment 7 June 2019
- Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval 12 April 2019
2018
- Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy 30 July 2018
- Astex’s Harren Jhoti Made Fellow of the Royal Society 9 May 2018
- Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation 15 March 2018
- Harren Jhoti Receives Lifetime Achievement Award from the UK BioIndustry Association 26 January 2018
- Otsuka Signs Statement of Support for Women’s Empowerment Principles 19 January 2018
2016
- Astex to Showcase Its Next-Generation Hypomethylating Agents Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology 29 November 2016
- Astex Joins the Dementia Discovery Fund as a Strategic Investor 21 November 2016
- Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (ribociclib) plus letrozole as a first-line treatment for HR+/HER2- Advanced Breast Cancer 1 November 2016
- Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka’s Subsidiary Astex Pharmaceuticals 20 October 2016
- Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia 19 April 2016
Selected past releases are archived for your reference.